• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.47% Nasdaq Up0.39%

    More On IMC.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Immuron Limited (IMC.AX)

    0.25 Down 0.02(7.41%) 1:46AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Immuron Limited
    18 Kavanagh Street
    Level 1
    Southbank, VIC 3006
    Australia - Map
    Phone: 61 3 8648 4530
    Fax: 61 3 9686 9460
    Website: http://www.immuron.com

    Index Membership:N/A
    Full Time Employees:16

    Business Summary 

    Immuron Limited, a biopharmaceutical company, researches, develops, and sells polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its platform technology enables the development of medicines that target a range of medical needs, such as infectious diseases, immune mediated disorders, and cancers. The company commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. It markets Travelan, a natural product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travellersÂ’ diarrhoea. The company is also developing IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/Type 2 diabetes, which is under Phase II clinical trial; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Southbank, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Immuron Limited

    Key Executives 
    Ms. Leearne Maree Hinch ,
    Chief Exec. Officer
    Mr. Phillip Allen Hains CA, MBA, 52
    Joint Chief Financial Officer and Joint Company Sec.
    Mr. Peter Vaughan ,
    Joint Chief Financial Officer and Joint Company Sec.
    Dr. Grant Rawlin B Sc (Vet) (Hons) B VSc,
    Chief Scientific Officer
    Mr. Arie L. Nudel B.Comm, B.Sci, 39
    Mang. Investor Relations
    Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.